title: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
authors.forename: E Gabriela
authors.initials: EG
authors.lastname: Chiorean
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Von Hoff
authors.forename: Josep
authors.initials: J
authors.lastname: Tabernero
authors.forename: Robert
authors.initials: R
authors.lastname: El-Maraghi
authors.forename: Wen
authors.initials: W
authors.lastname: Wee Ma
authors.forename: Michele
authors.initials: M
authors.lastname: Reni
authors.forename: Marion
authors.initials: M
authors.lastname: Harris
authors.forename: Robert
authors.initials: R
authors.lastname: Whorf
authors.forename: Helen
authors.initials: H
authors.lastname: Liu
authors.forename: Jack
authors.initials: J
authors.lastname: Shiansong Li
authors.forename: Victoria
authors.initials: V
authors.lastname: Manax
authors.forename: Alfredo
authors.initials: A
authors.lastname: Romano
authors.forename: Brian
authors.initials: B
authors.lastname: Lu
authors.forename: David
authors.initials: D
authors.lastname: Goldstein